A large Phase 3 trial found that a combination drug that contains the angiotensin II receptor blocker valsartan and the neprilysin inhibitor sacubitril was superior to the angiotensin-converting enzyme inhibitor enalapril in terms of death and hospitalization for heart failure in patients with heart failure with reduced ejection fraction. The Cleveland Clinic Journal of Medicine provides an overview of the study at http://www.ccjm.org/topics/cardiology/single-article-page/a-new-class-of-drugs-for-systolic-heart-failure-the-paradigm-hf-study/3c10470f58f8d999ac5a167730cc1515.html, along with the implications this new drug may have on the care of patients with chronic heart failure in the future.